# Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Canonical URL: https://biopharmsignal.com/news/DTIL/precision-biosciences-announces-new-and-late-breaking-pbgene-hbv-clinical-data-from-the-eliminate-b-study-at-european-association-for-the-study-of-the-liver-congress-2026
Ticker: DTIL
Company: Precision BioSciences
Source: Precision BioSciences
Published: 2026-06-25 13:46 EST
Original Source URL: https://investor.precisionbiosciences.com
## Summary

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts - - In the

## Article Body
- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts - - In the
## Recent Company News
- 2026-06-29 11:01 EST — [Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors](https://biopharmsignal.com/news/DTIL/precision-biosciences-announces-inclusion-in-the-russell-2000-index-expanding-ma-949bcb8c) — Source: Precision BioSciences
- 2026-06-25 13:46 EST — [Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026](https://biopharmsignal.com/news/DTIL/precision-biosciences-announces-new-and-late-breaking-pbgene-hbv-clinical-data-from-the-eliminate-b-study-at-european-association-for-the-study-of-the-liver-congress-2026) — Source: Precision BioSciences
- 2026-06-25 13:46 EST — [Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026](https://biopharmsignal.com/news/DTIL/precision-biosciences-to-host-investor-webcast-to-discuss-late-breaking-pbgene-hbv-data-from-eliminate-b-trial-presented-at-european-association-for-the-study-of-the-liver-congress-2026) — Source: Precision BioSciences
- 2026-06-25 13:46 EST — [Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting](https://biopharmsignal.com/news/DTIL/precision-biosciences-presents-new-preclinical-data-supporting-the-advancement-of-pbgene-dmd-into-clinic-at-the-american-society-of-gene-and-cell-therapy-2026-annual-meeting) — Source: Precision BioSciences
- 2026-06-25 13:46 EST — [Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program](https://biopharmsignal.com/news/DTIL/precision-biosciences-receives-u-s-patent-allowances-covering-the-pbgene-hbv-program) — Source: Precision BioSciences
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)